Hostname: page-component-74656f9884-2dmjx Total loading time: 0 Render date: 2026-11-07T20:19:36.256Z Has data issue: false hasContentIssue false

Evaluation of the therapeutic effect of Olibanum extract against enteric and intramuscular phases of trichinosis in experimentally infected mice

Published online by Cambridge University Press:  26 May 2023

A.M. Matar*
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Menoufia University, Shebin al-Kom, Menoufia, 6132720, Egypt
M.A. Kora
Affiliation:
Department of Pathology, Faculty of Medicine, Menoufia University, Shebin al-Kom, Menoufia, 6132720, Egypt
S.S. Shendi
Affiliation:
Department of Clinical and Molecular Parasitology, National Liver Institute, Menoufia University, Shebin al-Kom, Menoufia, 6132720, Egypt
*
Corresponding author: Amira M. Matar; Email: amira.matar@med.menofia.edu.eg
Rights & Permissions [Opens in a new window]

Abstract

Trichinosis is a global food-borne zoonotic disease. Most drugs used in its treatment have low bioavailability and reduced activity against larvae. Therefore, there is an urgent need for safe and effective medications. This study aimed to investigate the in vivo anti-parasitic and anti-inflammatory efficacy of olibanum (OL) extract, alone or combined with albendazole (ABZ) during both intestinal and muscular phases of trichinosis. Male Swiss albino mice (n = 130) were allocated to seven groups, with 20 mice in each group except for the negative control group (10 mice): negative control (GI), positive control (GII), OL25- treated (GIII), OL50- treated (GIV), ABZ50- treated (GV), OL25 + ABZ25 (GVI), and OL50 + ABZ25 (GVII). For intestinal and muscular phase analysis, each group was divided into two subgroups based on euthanizing day (6 and 35 days post-infection). The drug’s efficacy was evaluated through parasitological, biochemical, histopathological, and immunohistochemical studies. OL extract at both concentrations (25 mg/kg/d, 50 mg/kg/d) significantly reduced adult (53.7% and 68.1%, respectively) and larval counts (57.3% and 78.8%, respectively). It improved the histopathological changes in intestine and muscle. The expression of CD8+ T cells and the serum level of IL-10 increased significantly during both intestinal and muscular phases (P < 0.05) in OL50 treated mice. Additionally, OL decreased abnormal levels of liver enzymes (ALT & AST). Its effects were dose-dependent in both adult and larval stages. In conclusion, OL exhibits promising in vivo activity against both stages of Trichinella spiralis infection, particularly at the intramuscular phase. It can be safe as an alternative treatment for trichinosis.

Information

Type
Research Paper
Copyright
© The Author(s), 2023. Published by Cambridge University Press
Figure 0

Table 1. Comparison between different studied groups regarding adult worm count at 6 d.p.i. and encysted larvae number at 35 d.p.i.

Figure 1

Table 2. Comparison between different studied groups regarding concentrations of serum liver enzymes (ALT & AST) at 6 and 35 d.p.i.

Figure 2

Figure 1. IL-10 serum levels of mice in all studied groups at different times throughout the study. The results are represented by the mean ± SD per each group.

Figure 3

Figure 2. Intestinal phase of T.spiralis infected mice at 6 d.p.i. stained by H & E. (a) GI A with normal histology, the inset showed normal villous architecture; (b) GII A showing flattening of villi with widening of its core by oedema (red arrow) and dense chronic lymphoplasmacytic inflammatory infiltrate (black arrow); (c) GIII A with slight histological improvement with widening of core of many villi by oedema (red arrow) and chronic inflammatory infiltrate (black arrow); (d) GIV A exhibiting normal villous architecture with reduced number of inflammatory cells in villous core compared to infected group (black arrow); (e) GV A demonstrated marked improvement and a significant reduction in inflammatory infiltrate (black arrow); (f) GVI A with nearly similar morphology to GV A; (g) GVII A with normal villous architecture and marked reduction of lamina propria inflammatory infiltrate, (200X for A, C, E, & F and 400X for inset of A, B, D, & G).

Figure 4

Figure 3. Muscular phase of T. spiralis infected mice on 35 d.p.i. stained by H&E. (a) GI B with normal muscle histology; (b) GII B showing multiple encysted T.spiralis larvae diffusely present in muscles sarcoplasm (black arrow) surrounded by many chronic inflammatory cells (red arrow); (c) GIII B showing similar histological picture to GII B with many encysted T.spiralis larvae (black arrow) surrounded by chronic inflammatory infiltrate (red arrow); (d) & (e) GIV B with reduced number of degenerated larvae (black circles) invaded by inflammatory cells (black arrow); (f) GV B with improved morphology showing markedly degenerated larvae (black circles) invaded by inflammatory cells (black arrow); (g) GVI B with nearly similar picture to GV B showing chronic inflammatory infiltrate within degenerated muscle bundles; (h) GVII B with restoration of near normal muscle histology and complete absence of larvae, (200X for C and 400X for A, B, D, E, F, G, & H).

Figure 5

Figure 4. (a) Comparison between the studied groups regarding inflammatory score at 6 d.p.i. *P < 0.05 vs GII A; (b) Comparison between the studied groups regarding inflammatory score at 35 d.p.i. Data were expressed as percentage (n = 5 in GI B and 10 in all other groups). Post hoc test was used to make group comparison, *P < 0.05 vs GII B.

Figure 6

Figure 5. CD8+ IHC in intestinal phase. (a) GI A negative for CD8+ IHC; (b) GII A with low density of CD8+ T cells (black circles); (c) GIII A with few CD8+ T cells (black circles); (d) GIV A with high density of CD8+ T cells (black arrow); (e) GV A with low density of CD8+ T cells (black circles); (f) GVI A with increased CD8+ T cells (black arrow); (g) GVII A with dramatic increase of CD8+ T cells (black arrow), (IHC 200X for A & F and 400X for B, C, D, E, & G).

Figure 7

Figure 6. CD8+ IHC in muscular phase. (a) GI B negative for CD8+ IHC; (b) GII B with low density of CD8+T cells (black circles); (c) GIII B with few CD8+ T cells (black circle); (d) GIV B with high density of CD8+T cells (black arrow); (e) GV B with low density of CD8+ T cells (black circles); (f) GVI B with increased CD8+ T cells (black arrow); (g) GVII B with marked increase of CD8+T cells (black arrow), (IHC 400X for all).

Figure 8

Figure 7. (a) Comparison between the studied groups regarding CD8+ T cells count at 6 d.p.i.; (b) Comparison between the studied groups regarding CD8+ H score at 6 d.p.i. *P < 0.05 vs GII A; (c) Comparison between the studied groups regarding CD8+T cells count at 35 d.p.i.; (d) Comparison between the studied groups regarding CD8+ H score at 35 d.p.i. Data were expressed as mean ± SD (n = 5 in GI B and 10 in all other groups). Post hoc test was used to make group comparison. *P < 0.05 vs GII B.